Opposite Effects of Mepyramine on JNJ 7777120-Induced Amelioration of Experimentally Induced Asthma in Mice in Sensitization and Provocation by Beermann, Silke et al.
Opposite Effects of Mepyramine on JNJ 7777120-Induced
Amelioration of Experimentally Induced Asthma in Mice
in Sensitization and Provocation
Silke Beermann
1, Silke Glage
2, Danny Jonigk
3, Roland Seifert
1, Detlef Neumann
1*
1Institute of Pharmacology, Hannover Medical School, Hannover, Germany, 2Institute for Laboratory Animal Science, Hannover Medical School, Hannover, Germany,
3Institute of Pathology, Hannover Medical School, Hannover, Germany
Abstract
Background: Histamine is detected in high concentrations in the airways during an allergic asthma response. In a murine
model of allergic asthma, JNJ 7777120, an antagonist at the histamine H4 receptor, reduces asthmatic symptoms, while the
histamine H1 receptor-selective antagonist mepyramine is virtually without effect. In the present study, we analyzed the
effect of combined antagonism at the histamine H1 and H4 receptors in a murine asthma model in relation to the timing of
their application, i.e. sensitization or provocation.
Methodology/Principal Findings: Asthma was induced in mice by sensitization and provocation with ovalbumin. JNJ
7777120 and/or mepyramine were injected subcutaneously either during sensitization or during provocation, and typical
asthma parameters were analyzed. JNJ 7777120, but not mepyramine, reduced serum concentrations of anti-OVA IgE,
inflammatory infiltrations in lung tissue, and eosinophilia in bronchoalveolar-lavage (BAL)-fluids independently of the timing
of application. Upon application of JNJ 7777120 plus mepyramine in combination during provocation, mepyramine
inhibited the effects of JNJ 7777120. In contrast, when applied during sensitization, mepyramine enhanced the disease-
ameliorating effects of JNJ 7777120.
Conclusions/Significance: Our study indicates that both histamine H1 and H4 receptors play important roles in the course of
murine experimental asthma. Unexpectedly, the contribution of these receptors to the pathogenesis differs between the
two phases, sensitization or provocation. Since in human asthma, repeated contact to the allergen is not only provocation
but also a boost of sensitization, a combined pharmacological targeting of histamine H1 and H4 receptors could be taken
into consideration as an option for the prevention of asthma and maybe other allergic diseases.
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Introduction
Bronchial asthma is a complex disease of the airways, elicited
e.g. by a type I allergic response, with an increasing incidence
worldwide [1]. It is characterized by persistent airway inflamma-
tion and hyper-reactivity due to aberrant contractions of smooth
muscle cells and mucus production by goblet cells. A widely
accepted model of acute airway inflammation is the murine model
of ovalbumin (OVA)-induced allergic asthma [2,3]. In this model,
the pathogenesis of asthma can be clearly divided into sensitization
and provocation phase. In the sensitization phase, administration
of the allergen OVA elicits a Th2-type immune response resulting
in the production and systemic distribution of allergen-specific
immunoglobulin, of which a substantial proportion is of the IgE
isotype. Provocation by repeated inhalation of OVA then induces
an acute allergic reaction in the lung leading to local inflammation
and airway hyper-reactivity.
An important mediator in type I allergic reactions is the
biogenic amine histamine. Histamine concentrations in affected
tissue correlate well with severity of the allergic disease [4] and
topically applied histamine causes typical allergic symptoms [5].
Histamine exerts its effects through specific receptors on the
respective target cells. So far, four histamine receptors have been
identified. They belong to the family of G-protein-coupled 7-
transmembrane receptors and are referred to as histamine-1
receptor (H1R), H2R, H3R, and H4R [6–8]. In humans, type I
allergic symptoms, such as rhinitis and conjunctivitis, can be
controlled effectively by drugs antagonizing the activation of H1R,
with the exception of bronchial asthma [9]. In mice, genetic
deletion of the histamine-forming enzyme L-histidine decarbox-
ylase [10–12] or of H1R [13,14] provides beneficial effects in
experimental asthma. These data clearly reveal that histamine and
presumably also H1R are involved in the pathogenesis of bronchial
asthma, at least in the murine model. The recently identified H4R
[15–17] is a candidate receptor likely conveying histamine effects
in bronchial asthma. Although published data that demonstrate a
direct involvement of H4R in human asthma are not yet available,
in the experimental murine model, asthma symptoms are
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are reduced in H4R
2/2 mice [18,19].
In the present study, we asked the question whether H1R- and
H4R-selective antagonists cooperate in the murine model of
bronchial asthma, with respect to the two phases of the asthma
pathogenesis, sensitization and provocation. The H1R-selective
antagonist mepyramine [20] and the hH4R-selective antagonist
JNJ 7777120 [21,22] have been used for treatment in murine
OVA-induced asthma. We show that the ligands in combination
cooperatively reduce the allergic reaction when applied during
sensitization, whereas, in the provocation phase, mepyramine
antagonizes the beneficial effects of JNJ 7777120.
Results
1. JNJ 7777120-induced reduction of asthmatic
infiltrations is affected by mepyramine co-administration
In bronchoalveolar lavage (BAL)-fluids of mice with experi-
mental allergic asthma, enhanced numbers of cells are found as
compared to those found in sham-sensitized and provoked control
mice. This enhanced cellularity of the BAL-fluids is mainly due to
the occurrence of high numbers of eosinophils, which are virtually
absent in the controls [23]. A comparable enhanced cellularity was
observed in asthmatic mice after treatment with the solvent
DMSO as well as after treatment with the H1R-antagonist
mepyramine (Fig. 1). In contrast, treatment of asthmatic mice with
the hH4R-anatgonist JNJ 7777120 led to a reduction of BAL-fluid
eosinophil numbers. These observations were made irrespective of
the timing of the treatments, i.e. during provocation or during
sensitization. Quantitatively, JNJ 7777120 exhibited a more
pronounced effect upon its application during provocation
(275% vs DMSO) as compared to its application during
sensitization (231% vs DMSO). A major difference due to the
timing of application was observed when the two antagonists,
mepyramine and JNJ 7777120, were applied in combination.
Upon application during provocation, mepyramine inhibited the
effect of JNJ 7777120 on BAL-fluid eosinophil numbers (Fig. 1A).
When applied during sensitization, however, mepyramine poten-
Figure 1. Effect of mepyramine and JNJ 7777120 on BAL-fluid cellularity. Mice were sensitized to, and provoked with, OVA and treated with
DMSO, mepyramine, JNJ 7777120, or mepyramine plus JNJ 7777120 either 30 min before each provocation cycle (A) or 30 min before and 2 h after each
injection for sensitization (B). As control, mice were sensitized with PBS (sham), provoked with OVA, and treated with DMSO. Cells in BAL-fluids, collected 24 h
after the final challenge, were differentially counted. Data shown are means 6 SD (n(sham)=3,n (DMSO)=7,n (mepyramine, JNJ 7777120, or mepyramine+JNJ 7777120)=
8; *, p#0.05; **, p#0.01; ***, p#0.005).
doi:10.1371/journal.pone.0030285.g001
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reduction of eosinophil numbers as compared to the treatment
with JNJ 7777120 alone (Fig. 1B).
In lung tissue of asthmatic mice, inflammatory infiltrations with
lymphoid, monocytic and eosinophilic cells are found around
bronchi and vessels [24]. The quantification of the histological
sections by a scoring index revealed large inter-individual
variability within a treatment group (Figs. 2 B and D). However,
in lungs of DMSO-treated asthmatic mice a substantial number of
infiltrating cells was found (Figs. 2 A and C). This infiltration was
not affected by mepyramine treatment, when performed during
provocation (Fig. 2B), but a reduction was found, when
mepyramine was applied during sensitization (Fig. 2D). JNJ
7777120 treatment significantly reduced inflammatory lung
infiltration upon both, application during provocation and
sensitization. Also in both cases, co-administration of mepyramine
along with JNJ 7777120 did not reduce the JNJ 7777120 effect; it
was rather enhanced when mepyramine and JNJ 7777120 were
applied in combination during sensitization. The histology data
obtained from mice treated during provocation with the
combination of mepyramine and JNJ 7777120 are contradictory
to those data obtained by the analysis of BAL-fluids. This
discrepancy, however, can be explained methodologically. The
grading scheme used to quantify the histologic sections does not
Figure 2. Effect of mepyramine and JNJ 7777120 on airway inflammation. Mice were sensitized to, and provoked with, OVA and treated
with DMSO, mepyramine, JNJ 7777120, or mepyramine plus JNJ 7777120 either 30 min before each provocation cycle (A, B) or 30 min before and 2 h
after each injection for sensitization (C, D). A, C: Lungs were harvested, processed for histology, and sections were stained with H&E. Representative
pictures are shown. B, D: Sections as represented in A, C were evaluated in a blinded fashion using an index scoring the grade of inflammation.
(n(sham)=3,n (DMSO)=7,n (mepyramine, JNJ 7777120, or mepyramine+JNJ 7777120)=8; ***, p#0.005).
doi:10.1371/journal.pone.0030285.g002
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the peribronchial compartments. Thus, it does not reflect the
accessibility of individual inflammatory cells by BAL: leukocytes in
the bronchi/bronchioles are typically overrepresented in BAL-
fluids, while perivenular inflammatory changes are sampled only
to a minor degree [25,26]. This likely accounts for the discrepancy
between lung histology data and BAL-fluid data from mice treated
with the combination during the provocation phase: eosinophils
are concentrated around the veins and venules and not around
bronchi and bronchioles.
2. The Th2-type immune response in vivo is modulated
by mepyramine and JNJ 7777120
The occurrence of allergen-specific IgE is a hallmark of type I
allergic immune responses [27]. Thus, in sera of DMSO-treated
asthmatic mice anti-OVA IgE was found, while in sham-sensitized
and OVA-provoked mice such antibodies were not detectable
(Fig. 3 A and D). Mepyramine treatment of asthmatic mice, either
during provocation or during sensitization, did not affect anti-
OVA IgE concentrations in sera as compared to DMSO-treated
asthmatic mice. In contrast, JNJ 7777120 upon application during
provocation reduced the anti-OVA IgE concentration (Fig. 3A),
while upon application during sensitization there was only a
reduction without statistical significance (Fig. 3D). As already
observed by analyzing the cell numbers in BAL-fluids, co-
administration of mepyramine along with JNJ 7777120 reversed
the JNJ 7777120 effect when applied during provocation (Fig. 3A),
but seemed to enhance it when applied during sensitization
(Fig. 3D), although this is not supported by the statistical analysis.
Nonetheless, upon application during sensitization mepyramine
coadminisration did not antagonize the effect of JNJ 7777120, as
observed when applied during provocation. Allergic asthma is a
Th2-type immune response. Thus, cytokines such as IL- 5 and IL-
13 are found in enhanced quantities during such reaction [28].
Consequently, we found substantial concentrations of IL-5 and IL-
13 in sera of asthmatic mice, while they were lower or
undetectable in sera of sham-sensitized and OVA-provoked mice
(Fig. 3 B, C, E, F). In this assay, key cytokines typical for other
Figure 3. Effect of mepyramine and JNJ 7777120 on Th2 cytokine and anti-OVA IgE concentrations in sera. Mice were sensitized to,
and provoked with, OVA and treated with DMSO, mepyramine, JNJ 7777120, or mepyramine plus JNJ 7777120 either 30 min before each provocation
cycle (A, B) or 30 min before and 2 h after each injection for sensitization (C, D). In sera, collected 24 h after the final provocation, IL-13 concentrations
were measured by FlowCytomix (A, C) and anti-OVA IgE titers were determined by ELISA (B, D). Data shown are means 6 SD (n(sham)=3,n (DMSO)=7,
n(mepyramine, JNJ 7777120, or mepyramine+JNJ 7777120)=8;*,p#0.05; **, p#0.01; ***, p#0.005).
doi:10.1371/journal.pone.0030285.g003
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undetectable or unaltered, respectively (not shown). The applica-
tion of mepyramine or JNJ 7777120, either alone or in
combination, during provocation did not affect the serum
concentration of IL-13 (Fig. 3 B) or IL-5 (Fig. 3 C). In contrast,
upon application during sensitization, JNJ 7777120 in combina-
tion with mepyramine significantly reduced the IL-13 and IL-5
serum concentrations in comparison to the DMSO control, while
both ligands alone were without significant effect (Fig. 3 E, F).
3. The T cell response in vitro is modulated by
mepyramine and JNJ 7777120
Cells obtained from mesenteric lymph nodes of mice treated
during sensitization with DMSO, mepyramine, JNJ 7777120, or
mepyramine plus JNJ 7777120, which contained comparable
amounts of CD4
+ and CD8
+ cells (not shown), were re-stimulated
in vitro with OVA and analyzed for the expression of T cell specific
cytokines. In cells from DMSO-treated mice, the Th2-type
cytokines IL-4 and IL-5 were substantially expressed as well as
IFNc and IL-17, which are prototypical for Th1 and Th17 cells,
respectively. These cytokines were reduced in supernatants of cells
obtained from mice treated with mepyramine plus JNJ 7777120
(Fig. 4). The treatment of the mice with mepyramine or with JNJ
7777120 alone led to the reduced in vitro synthesis of IFNc or of
IFNc and IL-17, respectively, while IL-4 and IL-5 were not altered
significantly (Fig. 4). Other cytokine, IL-1a IL-2, IL-6, IL-10, were
detected in the supernatants, too, but without alterations of their
abundance due to the mepyramine/JNJ 7777120 treatment of the
mice (not shown).
Discussion
In the present study we analyzed the effects of mepyramine and
JNJ 7777120, antagonists at the H1R and H4R, respectively, in a
murine model of experimentally induced asthma. Particularly, we
compared their effects upon application during the sensitization
and the provocation phases.
While treatment of asthmatic mice with mepyramine had
virtually no effect on the disease parameters analyzed, asthmatic
symptoms were reduced by the application of JNJ 7777120. These
effects of the single treatment were independent of the timing of
application, sensitization or provocation. Similar observations with
JNJ 7777120 have already been published elsewhere [19], while it
has been shown previously, that mepyramine at 20 mg/kg body
weight during provocation was able to reduce BAL-fluid
eosinophilia [29]. This discrepancy is most likely due to differences
in the mode of application, since in the cited study, mepyramine
was injected twice daily and, in addition, already the day before
the initiation of the provocation phase [29].
The major topic of the present study is the application of the
H4R antagonist JNJ 7777120 [21] in combination with the H1R
antagonist mepyramine [20], either during the sensitization phase
or during the provocation phase. We observed an efficient
modulation of the JNJ 7777120 effect by mepyramine, which
was strictly dependent on the timing of application. Upon
application during provocation, mepyramine inhibited the effect
of JNJ 7777120, while during sensitization mepyramine enhanced
the symptoms-reducing effect of JNJ 7777120 (summarized in
table 1). This difference can be explained by the different target
cells, which are affected by histamine in the respective phase,
sensitization and provocation.
Sensitization basically is an immunoreaction against the
allergen, which takes place in the lymph nodes. Here, histamine
is produced most likely by dendritic cells and T cells and acts in an
autocrine manner, affecting T cells polarization [8]. In dendritic
cells and T cells, the H1R is involved in the regulation of cytokine
production [30,31] and the H4R regulates cytokine production,
antigen presentation, and cell migration [13,19,32]. Thus,
antagonism at both, H1R and H4R, may reduce the activation
of dendritic cells and/or T cells. However, so far there is no proof,
that H1R and H4R are expressed in parallel on the same cell in
vivo, since highly specific antibodies to detect these receptor
proteins in native cells are not available [33]. Therefore, we
cannot exclude the possibility, that mepyramine and JNJ 7777120
act on different target cells (two dendritic cell subsets, two T cell
subsets, dendritic cell and T cell), resulting in the observed effect.
Moreover, additional mechanism, constrained to the in vivo
situation, seem to be involved in this process, since the synergistic
effect of the mepyramine plus JNJ 7777120 treatment was not
detected in the in vitro assay using lymph node cells obtained from
treated mice.
During provocation, histamine is released by mast cell- or
basophil-degranulation resulting in rather high local concentra-
tions and affects peripheral cells such as mast cells, endothelial
cells, eosinophils, or polarized T cells. E.g. products released by
Th2 cells regulate growth and activation of eosinophils, thus,
playing a critical role in the pathogenesis of acute and chronic
asthma [34]. Here, the H4R may enhance the activation of
effector cells, while the H1R, either directly or indirectly via other
cells, reduces their activation.
Alternatively, the different effects due to the timing of
application of mepyramine and JNJ 7777120 may also be a
consequence of different histamine concentrations in the active
tissues [33], which are rather low in lymph nodes in contrast to
Figure 4. Effect of mepyramine and JNJ 7777120 on the T cell
cytokine production of lymph node cells after in vitro re-
stimulation. Mice were sensitized to OVA and treated with DMSO,
mepyramine, JNJ 7777120, or mepyramine plus JNJ 7777120 30 min
before and 2 h after each injection for sensitization. 48 h after the last
injection, single cells suspension out of mesenteric lymph nodes were
re-stimulated in vitro with OVA for 48 hours. Thereafter, accumulated
cytokines in the supernatants were quantified by a multiplex assay.
Data shown are means 6 SD (n(each group)=3*, p#0.05; **, p#0.01;
***, p#0.005).
doi:10.1371/journal.pone.0030285.g004
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agonist at the recombinant murine H4R expressed in Sf9 cells
[22,35], its actual function in vivo may depend on the local ratio of
histamine and JNJ 7777120, and thus may differ between the two
tissues [36]. Moreover, we do not know the expression levels of the
two receptors. When expressed on the same cell, the ratio of their
expression levels may differ between cells, resulting in different
effects as observed upon application of meypramine plus JNJ
7777120 in the provocation or the sensitization phase. In this
scenario also the concept of functional selectivity may apply [37–
39]. Particularly, in the lymph node JNJ 7777120 may act by
inhibition of H4R-mediated G-protein signaling [40], which is
potentiated by mepyramine, while in the periphery JNJ 7777120
may act via activation of ß-arrestin [41], which is inhibited by
mepyramine.
In conclusion, in the present study we provide evidence that
histamine via both, the H1R and the H4R, plays a critical role in
the pathogenesis of murine asthma. The contribution of the two
histamine receptors, however, differs between the two phases of
the pathogenesis, i.e. sensitization and provocation. This result is
unexpected and cannot be sufficiently explained by the current
paradigm of histamine receptor function. Therefore, the cellular
and molecular bases for this difference have yet to be identified,
inasmuch as the involvement of the H1R and the H4R in human
asthma has not been analyzed so far. However, our data indicate a
potential role for histamine receptor-antagonists also in the
therapy of human asthma.
The present study is limited by to the number of parameters
analyzed in order to characterize the type of immune response. In
order to unambiguously demonstrate the bias towards a Th2-type
response and/or its reversion towards a Th1- or a Th17-type
response, more markers need to be addressed. However, the major
topic of the present study is not a detailed analysis of the type of T
cell response, but the comparison of the effects of mepyramine plus
JNJ 7777120 as functions of time of their application, sensitization
or provocation. Although our data basically support our
conclusions, from a therapeutical point of view, functional analysis
such as lung function measurements are clearly missing in this
study. These technically challenging experiments will be provided
in a follow-up study. Moreover, additional parameters character-
izing in a detailed manner the underlying immune response will
have to be determined in future studies. Lastly, the pharmacoki-
netics of the applied antagonists, mepryamine and JNJ 7777120,
may differ from each other, possibly resulting in the observed
differences.
Materials and Methods
1. Ethics statement
All animal work has been conducted according to relevant
national and international guidelines and was performed under a
protocol approved by the local governmental authority (Nieder-
sa ¨chsisches Landesamt fu ¨r Verbraucherschutz und Lebensmittel-
sicherheit; approval ID 33.9-42502-04-08/1550).
2. Mice
Female Balb/c mice of 8 weeks of age were obtained from
Elevage Janvier (Le Genest-Saint-Isle, France), and housed in
community cages on a 12 h light cycle and fed mouse chow and
water ad libitum in the animal facility of the Hannover Medical
School. In order to enable their acclimatization, mice were kept
for at least 2-weeks in the animal facility before starting
experimental applications.
3. Sensitization and allergen challenge of mice
Experimental asthma was induced by sensitization with
endotoxin-free ovalbumin (OVA; Hyglos, Bernried, Germany)
and provocation with OVA grade V (Sigma-Aldrich, Taufkirchen,
Germany). The use of these two different preparations of OVA has
been shown in preliminary experiments to result in an optimal
asthmatic response. For sensitization, the mice were injected
intraperitoneally (i.p.) on days 1 and 14 with 10 mg of OVA, which
was absorbed to 1.5 mg of PBS-suspended aluminium hydroxide
(alum, Pierce Biotechnology, Rockford, IL, USA). In control
experiments, mice were sham-sensitized with alum/PBS. Provo-
cation was carried out at days 21–24 by daily exposition of mice to
1% (m/v) OVA/PBS for 20 min in a custom made nebulizer box
in which the mice could move freely.
4. H1R and H4R antagonist administration
The H1R-selective antagonist mepyramine (Sigma-Aldrich) and
the H4R selective antagonist JNJ 7777120 (1-[(5-chloro-1H-indol-
2-yl) carbonyl]-4-methylperazine, kindly provided by Dr. Armin
Buschauer, University of Regensburg, Germany) were dissolved in
20% (v/v) DMSO to obtain solutions of 10 mM. They were
administered in final doses of 20 mg/kg body weight [19,29]. The
mice sensitized and provoked with OVA were divided into four
experimental groups, which were treated either with 20% (v/v)
DMSO, with only mepyramine, with only JNJ7777120, or with a
combination of mepyramine and JNJ777120. Treatments were
performed by subcutaneous (s.c.) injections, using a total volume of
Table 1. Comparison of the effects of mepyramine, JNJ 7777120, and mepyramine+JNJ 7777120 on parameters of murine OVA-
induced experimental asthma.
application timing provocation sensitization
treatment mepy. JNJ 7777
mepy. +
JNJ 7777 mepy. JNJ 7777
mepy. +
JNJ 7777
serum aOVA IgE RQ R R(Q) Q
serum IL-13 R (Q) RR (Q) Q
lung histology RQ Q QQ Q
BALF eosinophilia RQ R RQ Q Q
impact of mepy. on JNJ 7777 treatment antagonistic synergistic
The effects of mepyramine, JNJ 7777120, or mepyramine plus JNJ 7777120 applied during either the provocation phase or the sensitization phases on selective
parameters observed in the experimental asthma model in this study were compared to the treatment with the solvent DMSO in the respective phase, and evaluated as
not altered [R], slightly reduced [(Q)], reduced [Q], and strongly reduced [QQ]. (mepy.: mepyramine, JNJ7777: JNJ 7777120).
doi:10.1371/journal.pone.0030285.t001
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tion phase, mice were treated 30 min before each OVA exposure.
For application in the sensitization phase, DMSO or antagonists
were administered 30 min before, and additionally 2 h after, OVA
injections. In preliminary experiments, it has been found that the
second administration of JNJ 7777120 two hours after OVA
injection is necessary to obtain an effect on the asthmatic response
[19]. A schematic representation of the experimental groups is
outlined in table 2.
5. Animal dissection
Mice were sacrificed with an i.p. injection of a mixture of
rompun (70 mg/kg bodyweight; Bayer, Leverkusen, Germany)
and ketamine (230 mg/kg bodyweight; Albrecht, Aulendorf,
Germany). Mice were bled by heart puncture and sera were
prepared and frozen at 280uC. Lungs were individually lavaged in
situ with 1.0 ml aliquots of sterile PBS (bronchoalveolar lavage:
BAL), and afterwards fixed in 4% (m/v) formaline and embedded
in paraffin.
6. Differential cell count
Total cell counts in BAL-fluids and viability were determined by
trypan blue exclusion using a Neubauer chamber. Leukocyte
populations (eosinophils, neutrophils, macrophages or lympho-
cytes) were counted in cytospins from BAL-fluids stained with Diff-
Quik (Medion Diagnostics, Dueningen, Germany). A total of 400
cells were counted in each sample.
7. Histology
Fixed and paraffin-embedded lungs were cut into 4 mm slices
and stained with hematoxilin/eosin. Representative microphoto-
graphs were taken using a Zeiss Axioskop 40 microscope with a
Zeiss AxioCam MRc camera. From each lung six sections
(containing hilus-structures and peripheral tisuue) of both lungs
were evaluated. Quantification of the bronchial inflammation was
performed according to a scoring index adapted from [42] ad
outlined in table 3.
8. In vitro stimulation of lymph node cells
Mice were sacrified 48 h after the last injection for sensitization.
Single cell suspension were prepared out of mesenteric lymph
nodes by teasing the organs and two times of repeated washing in
RPMI 1640 medium, supplemented with 5% [v/v] fetal calf
serum (FCS), 2 mM L-glutamate, 50 mM 2-mercaptoethanol,
100 U/ml penicillin, and 100 mg/ml streptomycin (all from PAA,
Pasching, Austria). Cells were resuspended in RPMI 1640 plus
supplements and 5610
5 cells/200 ml*well were plated in 96-well
plates (Nunc. Roskilde, Danmark) and re-stimulated in vitro with
50 mg/ml OVA for 48 hours. Thereafter, cell-free supernatants
were harvested and either analyzed immediately or stored at
280uC until use.
9. Evaluation of cytokine/chemokine concentrations
The cytokine concentrations in sera or in cell culture
supernatants were measured using the Mouse Th1/Th2 kit of
the FlowCytomix system (BenderMedSystems, Vienna, Austria).
The assay was performed according to the instructions supplied by
the manufacturer.
10. Mouse anti-OVA IgE ELISA
Serum concentrations of OVA-specific IgE were analyzed by
ELISA using a mouse-specific anti-IgE-antibody. Briefly, OVA-
coated microtiter plates (Nunc, Roskilde, Denmark) were incu-
bated with test sera, diluted 1:200 in PBS containing 5% (w/v)
BSA, and serial dilutions of a standard serum obtained from a
hyper-immunized mouse. Murine IgE was detected by subsequent
incubation with a biotinylated rat anti-mouse IgE antibody (BD/
Pharmingen, Franklin Lakes, NJ, USA) and peroxidase-coupled
Table 2. Experimental groups of mice.
group n sensitization provocation treatment
sham 3 PBS Ova DMSO
DMSO 7 Ova Ova DMSO
mepyramine 8 Ova Ova mepyramine
JNJ 7777120 8 Ova Ova JNJ 7777120
mepyramine +
JNJ 7777120
8 Ova Ova mepyramine +
JNJ 7777120
Mice, divided into the five groups indicated on the left, were either sham-
sensitized with PBS or sensitized with OVA. Provocation was carried out by
application of OVA in a nebulized form. Mice were treated either during
sensitization or during provocation with DMSO (sham; DMSO) or with
mepyramine and/or JNJ 7777120.
doi:10.1371/journal.pone.0030285.t002
Table 3. Histological scoring index.
grade N Histological appearance
0 N no focal infiltration or peribronchial or perivascular inflammatory infiltrates
1 N cuffs of leukocytes and eosinophils mostly around central bronchi and veins in a thin layer
N more lymphocytes than eosinophils
2 N cuffs of leukocytes and eosinophils around central bronchi and veins in a layer thicker than grade 1
N lymphocytes/eosinophils ratio: 50/50
N no/some aggregates of inflammatory cells in lung parenchyma
3 N cuffs of leukocytes and eosinophils around central bronchi and veins and up to 2/3 of periphery
N lymphocytes/eosinophils ratio: 50/50
N some aggregates of inflammatory cells in lung parenchyma
4 N cuffs of leukocytes and eosinophils around all visible bronchi and veins up to pleura
N eosinophilic cells diffuse in lung parenchyma
N aggregates of inflammatory cells diffuse in lung parenchyma
The scoring index was adapted from Mehlhop et al [42] with minor modifications. According to this index, inflammatory infiltrations observed in lung tissues sections
(figure 2) were quantified.
doi:10.1371/journal.pone.0030285.t003
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idase-dependent conversion of TMB was quantified by reading at
405 nm. Titers were calculated according to the standard serum
obtained from a hyper-immunized mouse, which was set
arbitrarily at 1610
6 U/ml.
11. Statistical analysis
If not stated otherwise, statistical analyses were performed by
calculating means 6 SD for each parameter within an
experimental group. Analysis of significance was performed using
one-way ANOVA with Bonferroni post test for linear parameters
or the chi-square (Fisher’s exact) test for categorical data (both
GraphPad Prism 5). p-Values of ,0.05 (*), ,0.01 (**), and ,0.005
(***) were considered significant.
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